[1]罗全勇.多肽受体靶向放射治疗:现状与进展[J].国际放射医学核医学杂志,2005,29(2):74-78.
　LUO Quan-yong.Peptide receptor radionuclide therapy: current status and future directions[J].International Journal of Radiation Medicine and Nuclear Medicine,2005,29(2):74-78.
点击复制

多肽受体靶向放射治疗:现状与进展(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
29
期数:
2005年第2期
页码:
74-78
栏目:
核医学
出版日期:
1900-01-01

文章信息/Info

Title:
Peptide receptor radionuclide therapy: current status and future directions
作者:
罗全勇
200233 上海, 上海交通大学附属第六人民医院核医学科
Author(s):
LUO Quan-yong
Department of Nuclear Medicine, Shanghai Sixth People’s Hospital, Shanghai Jiao Tong University, Shanghai 200233, China
关键词:
多肽; 放射性核素治疗; 生长抑素
Keywords:
peptides; radionuclide therapy; somatostatin
分类号:
R817.5
摘要:
临床前及临床多中心试验结果已证实应用放射性核素标记的生长抑素类似物进行多肽受体靶向放射治疗(PRRT)的有效性,不同治疗手段联合治疗能进一步提高PRRT的临床疗效,177Lu与90Y标记的生长抑素类似物联合治疗可以获得更好的疗效,其受体在前列腺与乳腺癌等常见肿瘤细胞上表达的蛙皮素和神经肽Y类似物正在研究中。联合放射性核素标记的蛙皮素和神经肽Y类似物进行多受体肿瘤靶向治疗对于乳腺癌及其淋巴结转移灶的诊断与PRRT也很有希望。
Abstract:
Results from preclinical and clinical multicenter studies with radiolabeled somatostatin ana-logues for peptide receptor radionuclide therapy(PRRT) already have shown an effective therapeutic response. The combination of different therapy modalities holds interest as a means of improving the clinical therapeutic effects of radiolabeled peptides. The combination of different radionuclides, such as 177Lu- and 90Y-labeled somatostatin analogues, to reach a wider tumor region of high curability, has been described. A variety of other peptide-based radioligands, such as bombesin and NPYanalogues, receptors for which are expressed on common cancers such as prostate and breast cancer, are currently under development. Multireceptor tumor targeting using the combination of bombesin and NPY analogues is promising for scintigraphy and PRRT of breast carcinomas and their lymph node metastases.

参考文献/References:

1 Reubi JC. Somatostatin and other peptide receptors as tools for tumor diagnosis and treatment[J]. Neuroendocrinology, 2004, 80(Suppll):51-56.
2 Blum J, Handmaker H, Lister-James J, et al. A multicenter trial with a somatostatin analog (99m)Tc depreotide in the evaluation of solitary pulmonary nodules[J]. Chest, 2000, 117(12):1232-1238.
3 Reubi JC, Schar JC, Waser B, et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for seintigraphic and radiotherapeutic use[J]. Eur J Nucl Med, 2000, 27(2):273-282.
4 McCarthy KE, Woltering EA, Anthony LB. In situ radiotherapy with 111In-pentetreotide. State of the art and perspectives[J]. Q J Nuel Med,2000, 44(1):88-95.
5 Anthony LB, Woltering EA, Espenan GD, et al. Indium-111-pentetreotide prolongs survival in gastroenteropanereatic malignancies[J].Semin Nuel Med, 2002, 32(1):123-132.
6 Valkema R, De Jong M, Bakker WH, et al. Phase I study of peptide receptor radionuclide therapy with[In-DTPA]octreotide:the Rotterdam experience[J]. Semin Nucl Med, 2002, 32(1):110-122.
7 Chinol M, Bodei L, Cremonesi M, et al. Receptormediated radiotherapy with Y-DOTA-dPhe-Tyr-octreotide:the experience of the European Institute of Oncology Group[J]. Semin Nucl Med, 2002,32(2):141-147.
8 Paganelli G, Zoboli S, Cremonesi M, et al. Receptor-mediated radiotherapy with 90Y-DOTA-d-Phel-Tyr3-octreotide[J]. Eur J Nucl Med, 2001, 28(3):426-434.
9 Paganelli G, Bodei L, Chinol M, et al. Receptor mediated radiotherapy with 90Y-DOTATOC:results of a phase Ⅰ study[J]. J Nucl Med,2001, 42(1):36P.
10 Waldherr C, Pless M, Maecke HR, et al. The clinical value of 90Y-DOTA]-d-Phel-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours:a clinical phase Ⅱ study[J]. Ann Oncol,2001, 12(6):941-945.
11 Waldherr C, Pless M, Maecke HR, et al. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq 90Y-DOTATOC[J]. J Nucl Med, 2002, 43(4):610-616.
12 De Jong M, Valkema R, Jamar F, et al. Somatostatin receptor-targeted radionuclide therapy of tumors:preclinical and clinical findings[J].Semin Nucl Med, 2002, 32(1):133-140.
13 Smith MC, Liu J, Chen T, et al. OctreoTher:ongoing early clinical development of a somatostatin- receptor-targeted radionuclide antineoplastic therapy[J]. Digestion, 2000, 62(Suppl 1):69-72.
14 Valkema R, Kvols L, Jamar F, et al. Phase 1 study of therapy with 90Y-SMT487(OctreoTher) in patients with somatostatin receptor-positive tumors[J]. J Nucl Med, 2002, 43(1):33P.
15 Bushnell D, Menda Y, Madsen M, et al. Assessment ofhepatic toxicity from treatment with 90Y-SMT 487(OctreoTher(TM)) in patients with diffuse somatostatin receptor positive liver metastases[J]. Cancer Biother Radiopharm, 2003, 18(4):581-588.
16 Bodei L, Handkiewicz-Junak D, Grana C, et al. Receptor radionuclide therapy with 90Y-DOTATOC in patients with medullary thyroid carcinomas[J]. Cancer Biother Radiopharm, 2004, 19(1):65-71.
17 Pless M, Waldherr C, Maecke H, et al. Targeted radiotherapy for small cell lung cancer using 90Y-DOTATOC, an Yttriumlabelled somatostatin analogue:a pilot trial[J]. Lung Cancer, 2004, 45(3):365-371.
18 Schumacher T, Hofer S, Eichhorn K, et al. Local injection of the90Y-labelled peptidic vector DOTATOC to control gliomas of WHO grades Ⅱ and Ⅲ:an extended pilot study[J]. Eur J Nucl Med Mol Imag, 2002, 29(2):486-493.
19 Virgolini I, Britton K, Buscombe J, et al. In- and Y-DOTA-lanreotide:results and implications of the MAURITIUS trial[J]. Semin Nucl Med, 2002, 32(1):148-155.
20 Virgolini I, Traub T, Novotny C, et al. Experience with indium-111and yttrium-90-labeled somatostatin analogs[J]. Curr Pharm Des,2002, 8(12):1781-1807.
21 de Jong M, Breeman WA, Bernard BF, et al.[177Lu-DOTA(0), Tyr3] octreotate for somatostatin receptor-targeted radionuclide therapy[J]. Int J Cancer, 2001, 92(4):628-633.
22 Kwekkeboom DJ, Bakker WH, Kam BL, et al. Treatment with[177LuDOTA0, Tyr3] octreotate in patients with neuroendocrine tumors:interim results[J]. EurJ Nucl Med, 2003, 30(Suppl 2):S231.
23 Boerman OC, Oyen WJ, Corstens FH. Between the Scylla andCharybdis of peptide radionuclide therapy:hitting the tumor and saving the kidney[J]. Eur J Nucl Med, 2001, 28(10):1447-1449.
24 Rolleman EJ, Valkema R, de Jong M, et al. Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine[J]. Eur J Nucl Med Mol Imaging, 2003, 30(1):9-15.
25 Behr TM, Behe MP. Cholecystokinin-B/gastrin receptor-targeting peptides for staging and therapy of medullary thyroid cancer and other cholecystokinin-B receptor-expressing malignancies[J]. Semin Nucl Med, 2002, 32(1):97-109.
26 Schmitt JS, Wild D, Ginj M, et al. DOTA-NOC, a high affinity ligand of the somatostatin receptor subtypes 2,3 and 5 for radiotherapy[J]. J Labelled Cpd Radiopharm, 2001, 44(3):s697-s699.
27 De Jong M, Bernard HF, Breeman WAP, et al. Combination of 90Y-and 177Lu-labeled somatostatin analogs is superior for radionuclide therapy compared to 90Y- or 177Lu-labeled analogs only[J]. J Nucl Med, 2002, 43(1):123P-124P.
28 Verwijnen SM, Sillevis Smith PA, Hoeben RC et al. Molecular imaging and treatment of malignant gliomas following adenoviral transfer of the herpes simplex virus-thymidine kinase gene and the somatostatin receptor subtype 2 gene[J]. Cancer Biother Radiopharm,2004, 19(1):111-120.
29 Gugger M, Reubi JC. Gastrin-releasing peptide receptors in nonneoplastic and neoplastic human breast[J]. Am J Pathol, 1999, 155(11):2067-2076.
30 Reubi C, Gugger M, Waser B. Co-expressed peptide receptors in breast cancer as a molecular basis for in vivo multireceptor tumour targeting[J]. Eur J Nucl Med Mol Imaging, 2002, 29(3):855-862.

相似文献/References:

[1]杨卫东,汪静.肿瘤核素靶向治疗新进展[J].国际放射医学核医学杂志,2015,39(1):19.[doi:10.3760/cma.j.issn.1673-4114.2015.01.006]
　Yang Weidong,Wang Jing.Advance progress of radionuclide target tumor therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(2):19.[doi:10.3760/cma.j.issn.1673-4114.2015.01.006]
[2]罗全勇,朱瑞森.rhTSH在甲状腺疾病治疗中的潜在价值[J].国际放射医学核医学杂志,2005,29(2):63.
　LUO Quan-yong,ZHU Rui-sen.Potential therapeutic uses for rhTSH in thyroid diseases[J].International Journal of Radiation Medicine and Nuclear Medicine,2005,29(2):63.
[3]周玉凤.放射性核素标记小分子多肽治疗肿瘤的研究进展[J].国际放射医学核医学杂志,2005,29(3):105.
　ZHOU Yu-feng.The recent development of receptor targeting therapy for tumors with radiopeptides[J].International Journal of Radiation Medicine and Nuclear Medicine,2005,29(2):105.
[4]张一帆,李彪.钠/碘同向转运体在甲状腺癌131I治疗中的应用[J].国际放射医学核医学杂志,2004,28(6):249.
　ZHANG Yi-fan,LI Biao.Application of sodium/iodide symporter gene in thyroid cancer for radiotherapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2004,28(2):249.
[5]向艳,夏劲松.生长抑素类似物及其标记核素[J].国际放射医学核医学杂志,2002,26(1):21.
　XIANG Yan,XIA Jin-song.Recent development of radio-labeled somatostatin analogues as receptor image agent[J].International Journal of Radiation Medicine and Nuclear Medicine,2002,26(2):21.
[6]杨永青.标记免疫分析在心血管疾病中的临床价值及其进展[J].国际放射医学核医学杂志,2000,24(5):193.
　YANG Yong-qing.The clinical applications of labelling immunoassay in the cardiovascular disease and its progress[J].International Journal of Radiation Medicine and Nuclear Medicine,2000,24(2):193.
[7]卢倜章.131I治疗甲状腺疾病的研究趋向[J].国际放射医学核医学杂志,2000,24(3):97.
　LU Ti-zhang.Current trend of research on 131I therapy for thyroid diseases[J].International Journal of Radiation Medicine and Nuclear Medicine,2000,24(2):97.
[8]王晓青,谢毓元.以多肽导向的靶向造影剂的研究[J].国际放射医学核医学杂志,1996,20(2):49.
[9]王任飞,田小丽,谭建,等.腰椎能谱CT评估Graves甲状腺功能亢进症患者131I治疗前后骨量变化的价值[J].国际放射医学核医学杂志,2018,(6):495.[doi:10.3760/cma.j.issn.1673-4114.2018.06.004]
　Wang Renfei,Tian Xiaoli,Tan Jian,et al.Changes of bone mass in patients with Graves’ hyperthyroidism before and after 131I therapy based on CT spectral imaging[J].International Journal of Radiation Medicine and Nuclear Medicine,2018,(2):495.[doi:10.3760/cma.j.issn.1673-4114.2018.06.004]

备注/Memo

备注/Memo:
收稿日期:2005-01-31。
更新日期/Last Update: 1900-01-01